Dear Veterans Service Organization Leaders, Veterans Advocates, and my fellow brother and sister veterans,
I am writing to alert you to a significant regulatory change issued by the U.S. Department of Veterans Affairs that has immediate and potentially far-reaching consequences for disability compensation.
On February 17, 2026, VA published an interim final rule amending 38 C.F.R. ? 4.10, fundamentally changing how disability ratings account for the impact of medication and treatment. The rule, which had taken effect immediately, has been backpedaled by the Secretary of Veterans Affairs- at least for the moment. Regardless, public comments on this dubious rule are due by April 20, 2026.
What the Rule Does
VA has directed examiners to:
* Disregard any estimate of an untreated (unmedicated) baseline condition
* Rate disabilities as they present while medicated
* Not discount symptom improvement resulting from medication or treatment
In practical terms, if medication lowers the observable severity of a service-connected disability, the rating will now be based on that reduced presentation.
Before This Change
VA could not deny or reduce ratings solely because medication relieved symptoms. The evaluation focused on the veteran’s underlying functional impairment.
Under the New Rule
Examiners must rate the disability as it appears with medication onboard, without considering the unmedicated baseline severity.
Process Concerns
* Veterans Service Organizations were not consulted prior to issuance.
* Disabled American Veterans has publicly stated that the expedited process represents a “shut out” of meaningful veteran input.
* Veterans of Foreign Wars has likewise raised concerns.
* The House Subcommittee on Disability Assistance and Memorial Affairs held a January hearing on VASRD updates and was not informed that this interim final rule was forthcoming.
Why This Matters
This rule change:
* Conflicts with judicial precedent requiring evaluation of underlying impairment.
* Creates downward pressure on compensation.
* Penalizes veterans for adhering to prescribed treatment.
* Forces veterans into an untenable position: manage symptoms effectively or risk reduced compensation.
Disability compensation is intended to reflect the severity of a service-connected condition — not how effectively it can be chemically suppressed.
If medication reduces observable symptoms, the rating will now be lowered accordingly. This could affect:
* A veteran with severe migraines controlled by medication.
* A veteran whose PTSD symptoms are stabilized through pharmaceuticals.
* A veteran whose orthopedic pain is managed just enough to function.
The implications are serious:
1. Veterans whose conditions require ongoing medication may see reduced compensation.
2. The rule may discourage treatment adherence by creating fear that symptom control will result in benefit reduction.
Veterans should never have to choose between caring for their health and preserving the benefits they earned through service.
Action Requested
We respectfully ask your organizations to:
* Inform your members and networks immediately.
* Consider submitting formal organizational comments.
* Encourage individual veterans to submit comments before April 20, 2026.
Comments may be submitted at:
https://www.regulations.gov/document/VA-2026-VBA-0067-0001
Our office stands with the veterans’ community in ensuring that disability compensation policy reflects both fairness and the realities of service-connected conditions. We welcome your feedback, data, and constituent impact stories as we evaluate next steps.
Please share this information broadly.
Respectfully at your service,
John E. Helcl II, MPA (he/him)
Veterans Constituent Advocate
U.S. Army Veteran
Office of Rep. Angie Craig (MN-02)
W: (651) 846-2120
C: (202) 841-2130
Scheduled office hours: M, W, F, 9 am – 2 pm; or by appointment.
